Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use - Université de Bretagne Occidentale Access content directly
Journal Articles Pharmaceuticals Year : 2022

Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use

Frédérique Blanc-Béguin
Simon Hennebicq
  • Function : Author
Philippe Robin
  • Function : Author
Pierre-Yves Salaün
  • Function : Author
Pierre-Yves Le Roux

Abstract

Lung ventilation/perfusion (V/Q) positron emission tomography-computed tomography (PET/CT) is a promising imaging modality for regional lung function assessment. The same carrier molecules as a conventional V/Q scan (i.e., carbon nanoparticles for ventilation and macro aggregated albumin particles for perfusion) are used, but they are labeled with gallium-68 (68Ga) instead of technetium-99m (99mTc). For both radiopharmaceuticals, various production processes have been proposed. This article discusses the challenges associated with the transition from 99mTc- to 68Ga-labelled radiopharmaceuticals. The various production and optimization processes for both radiopharmaceuticals are reviewed and discussed for optimal clinical use.

Dates and versions

hal-04545863 , version 1 (14-04-2024)

Identifiers

Cite

Frédérique Blanc-Béguin, Simon Hennebicq, Philippe Robin, Raphaël Tripier, Pierre-Yves Salaün, et al.. Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. Pharmaceuticals, 2022, 15 (5), pp.518. ⟨10.3390/ph15050518⟩. ⟨hal-04545863⟩
12 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More